Novo Nordisk stock news
On June 11, 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk's (NVO) Wegovy pill (semaglutide tablets) for weight management, marking the first daily GLP--1 tablet authorized in the United Kingdom. The approval, supported by data from the OASIS 4 phase 3 trial showing significant weight reduction, positions the UK as the first European nation to clear the oral formulation. Shares of NVO rose approximately 3% on the news, as the approval represents a strategic expansion of the company's metabolic franchise into the European market, providing a non--injectable alternative for patients with obesity.